Lincoln Pharma Peer Comparison

NSE: LINCOLN | BSE: 531633

₹614.95

₹0.95 (0.15%)

As on 28-Aug-2026IST

Market cap

₹1,233 Cr

Revenue (TTM)

₹694 Cr

P/E Ratio

12.8

P/B Ratio

1.6

Div. Yield

0.3 %

Edit

	Lincoln Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Market cap (₹ Cr)	1,233	21,501	19,125	18,253	17,766
Revenue (₹ Cr)	694	2,570	2,287	3,230	2,432
Net Profit (₹ Cr)	96.45	735.15	678.07	666.92	169.62
Net Margin (%)	13.09	26.88	28.10	20.60	6.90
RoE (%)	13.09	19.16	19.73	18.75	20.76
Price to Earnings	12.78	29.25	28.74	28.35	104.74
Price-To-Book	1.55	4.88	5.08	4.51	19.65

Income Statement (₹ Cr)

	Lincoln Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Operating Revenue	694.25	2,569.77	2,287.33	3,229.67	2,432.06
Total Income	736.69	2,735.39	2,413.29	3,237.12	2,458.54
Total Expenditure	592.94	1,628.14	1,490.75	2,090.06	2,202.20
EBITDA	101.31	941.63	796.58	1,139.61	229.86
Depreciation	14.91	57.58	78.10	281.06	17.24
EBIT	86.40	884.05	718.48	858.55	212.62
Interest	1.06	7.69	0.88	190.64	5.72
Other Income	42.45	165.62	125.96	7.45	26.48
Exceptional Items	0.00	-49.16	0.00	-17.24	-5.13
Profit before Tax	127.79	992.82	843.56	658.12	228.25
Provision for Tax	31.34	257.67	165.49	-8.80	58.63
Profit after Tax	96.45	735.15	678.07	666.92	169.62

	Lincoln Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Shareholder's Funds	757.63	4,202.90	3,586.42	3,902.67	872.79
Minority Interest	0.00	0.00	-12.71	-21.81	0.00
Non-Current Liabilities	21.73	91.50	28.74	1,392.75	134.50
Current Liabilities	111.05	627.48	385.94	2,077.10	981.81
Total Liabilities	821.88	4,911.11	3,207.85	6,862.28	1,879.19

	Lincoln Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Non-Current Assets	302.96	770.28	1,291.22	5,617.77	42.47
Current Assets	583.06	3,803.22	2,585.66	1,539.85	1,739.93
Total Assets	821.88	4,911.11	3,207.85	6,862.28	1,879.19
Total Debt*	0.00	2.50	0.55	2,421.66	0.00
Net Current Assets	472.01	3,175.74	2,199.72	-537.25	758.12
Contingent Liabilities	3.12	363.79	0.64	64.29	98.41

	Lincoln Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Cash From Operating Activities	93.02	659.75	432.37	1,065.01	65.36
Cash Flow from Investing Activities	-78.95	-71.34	-334.73	-79.97	30.80
Cash from Financing Activities	-6.40	-205.34	-38.32	-881.32	-65.59
Net Cash Inflow / Outflow	7.67	383.07	59.32	103.72	30.57

	Lincoln Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
ROCE (%)	17.55	26.21	26.22	13.59	21.29
ROE (%)	13.09	19.16	19.73	18.75	20.76
ROA (%)	11.43	14.95	18.69	9.26	9.67
EBIT Margin (%)	12.45	34.40	31.41	26.58	8.74
Net Margin (%)	13.09	26.88	28.10	20.60	6.90
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Lincoln Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Revenue Growth (%)	10.19	10.69	15.01	9.59	31.10
EBIT Growth (%)	-3.37	24.14	18.45	16.84	-12.99
Net Profit Growth (%)	11.70	-9.09	19.61	62.68	-7.49
EPS Growth (%)	11.70	14.40	17.73	67.41	-18.33
Book Value Growth (%)	13.30	17.30	23.77	10.19	7.70

	Lincoln Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Price / Earnings	12.78	27.87	28.74	27.66	102.37
Price / Book Value	1.55	4.88	5.08	4.51	19.65
Dividend Yield (%)	0.29	1.60	0.16	0.55	0.51
EV/EBITDA	10.23	19.53	22.88	17.94	75.34
Market Cap (₹ Cr)	1,104.74	18,318.10	15,219.80	19,292.77	21,515.93

	Lincoln Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debt to Equity	0.00	0.00	0.00	0.24	0.00
Short term debt to equity ratio	--	0.00	0.00	0.14	--
Current Ratio	5.25	6.06	6.70	0.74	1.77
Quick Ratio	4.53	5.31	5.59	0.53	0.73
Interest Coverage	121.33	130.11	959.59	4.45	40.90

	Lincoln Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debtors to sales (%)	23.26	7.07	36.10	21.07	8.79
Asset Turnover	0.82	0.52	0.63	0.45	1.39
Receivable days	91.75	29.10	110.70	54.07	35.81
Inventory Days	43.57	69.53	65.86	32.16	82.25
Payable days	141.73	76.77	105.88	140.91	124.39
Cash Conversion Cycle	-6.41	21.86	70.68	-54.68	-6.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.